Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review)

Int J Mol Med. 2024 Dec;54(6):105. doi: 10.3892/ijmm.2024.5429. Epub 2024 Sep 20.

Abstract

Liver fibrosis is a pathophysiologic manifestation of chronic liver disease and a precursor to cirrhosis and hepatocellular carcinoma. Glycolysis provides intermediate metabolites as well as energy support for cell proliferation and phenotypic transformation in liver fibers. 6‑Phosphofructo‑2‑kinase/fructose‑2,6‑bisphosphatase 3 (PFKFB3) is a key activator of glycolysis and plays an important role in the process of glycolysis. The role of PFKFB3‑mediated glycolysis in myocardial fibrosis, renal fibrosis and pulmonary fibrosis has been demonstrated, and the role of PFKFB3 in the activation of hepatic stellate cells by aerobic glycolysis has been proven by relevant experiments. The present study reviews the research progress on the role and mechanism of action of PFKFB3‑mediated glycolysis in the progression of hepatic fibrosis to discuss the role of PFKFB3‑mediated glycolysis in hepatic fibrosis and to provide new ideas for research on PFKFB3 as a target for the treatment of hepatic fibrosis.

Keywords: PFKFB3; glycolysis; hepatic stellate cells; liver fibrosis; metabolic reprogramming.

Publication types

  • Review

MeSH terms

  • Animals
  • Glycolysis*
  • Humans
  • Liver Cirrhosis* / metabolism
  • Liver Cirrhosis* / pathology
  • Phosphofructokinase-2* / genetics
  • Phosphofructokinase-2* / metabolism

Substances

  • Phosphofructokinase-2
  • PFKFB3 protein, human

Grants and funding

The present study was supported by grants from the National Natural Science Foundation of China (grant nos. 82460466, 81960507 and 82073087), the Science and Technology Plan Project of Guizhou Province [grant no. QIAN KE HE JI CHU-ZK(2024)YI BAN 323] and the Collaborative Innovation Center of the Chinese Ministry of Education (grant no. 2020-39).